Highly specialized medical device maker MiniMed Group (MMED +0.34%) was highly prized by investors over the past few trading days. That stood to reason, as the company unveiled first-quarter fiscal 2027 results that comfortably exceeded revenue expectations.
As of late Thursday evening, the company's shares were up by nearly 19% week to date, according to data compiled by S&P Global Market Intelligence.
Pumped for growth
MiniMed, which focuses on diabetes care, booked net sales of $843 million, up a sturdy 17% year over year. Much of this came from outside our borders, as international net sales rose by 18% to hit $603 million. That figure for the medical device company's native U.S. market was $240 million, 13% higher than the same quarter of fiscal 2026.
Image source: Getty Images.
On the bottom line, MiniMed hit breakeven, an improvement over the $19 million net loss it posted in the year-ago frame.
That top-line result handily beat the average analyst estimate of just under $827 million. A consensus net income number was not immediately available.
One highlight of the quarter was the launch of MiniMed Flex, an insulin pump. It was introduced to the U.S. market as a system in combination with the company's Simplera glucose monitoring device.
MiniMed said of the new product that it "is doing exactly what we designed it to do: bringing new patients into the MiniMed ecosystem, driving competitive conversions, and generating significant new account growth."
NASDAQ: MMED
Key Data Points
Guidance bump
MiniMed boosted its full-year revenue guidance, albeit modestly. It's now modeling 10.5% growth over the fiscal 2026 figure; previously, it had anticipated roughly a 10% rise. Management also reaffirmed its previous guidance of 16% growth for adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA).
The U.S. launch of MiniMed Flex is only the start of a series of worldwide product rollouts, so its maker clearly has notable momentum. And while it's a niche company, diabetes has a significant global patient population that could use its wares. I'd say these factors make its stock worth considering as a buy.
